Printer Friendly

AFFINITY BIOTECH ANNOUNCES AGREEMENT WITH AMERICAN HOME PRODUCTS

 AFFINITY BIOTECH ANNOUNCES AGREEMENT WITH AMERICAN HOME PRODUCTS
 BOOTHWYN, Pa., Aug. 27 /PRNewswire/ -- Affinity Biotech, Inc. (NASDAQ: AFBI) today announced that it has entered into an option agreement with Whitehall Laboratories, a division of American Home Products Corporation (NYSE: AHP). Under the agreement, Whitehall obtained an option to license Affinity's taste-masked chewable formulation of a wisely used OTC pharmaceutical after the completion of a pilot development program. For Affinity, the development of taste- masked chewable and liquid products is an extension of the company's expertise in the application of surface chemistry to pharmaceutical formulations.
 In February 1992, SmithKline Beecham plc licensed Affinity's taste- masked formulation of a liquid version of one of SmithKline's major products which is now in human clinical trials. The agreements with SmithKline and Whitehall exemplify the progress Affinity has made in commercializing its taste-masking technology.
 "This source of near-term product revenues distinguishes Affinity from most other development-stage biotechnology companies," said Alan Dickason, Ph.D., president and chief executive officer of Affinity.
 Based in Boothwyn, Pa., Affinity Biotech focuses on the development of oral drug delivery systems for patients and other therapeutic agents, taste masking of therapeutic agents, the development of synthetic blood, and other microemulsion-based pharmaceutical products.
 -0- 8/27/92
 /CONTACT: Wayne B. Weisman, executive vice president of Affinity Biotech, Inc. 215-497-0500, or Anthony J. Russo or Alexander A. Fudukidis of Noonan/Russo Communications, Inc. 212-979-9180, for Affinity Biotech, Inc./
 (AFBI AHP) CO: Affinity Biotech, Inc.; American Home Products Corp. ST: Pennsylvania, New York IN: MTC SU:


TS-OS -- NY016 -- 3804 08/27/92 09:16 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 27, 1992
Words:261
Previous Article:BUTTREY FOOD AND DRUG STORES CO. ANNOUNCES EARNINGS FOR THE SECOND QUARTER OF 31 CENTS PER SHARE VERSUS 14 CENTS PER SHARE
Next Article:HEALTH MANAGEMENT ASSOCIATES HOSPITALS ESCAPE DAMAGE BY HURRICANE
Topics:


Related Articles
AFFINITY BIOTECH ANNOUNCES FIRST QUARTER RESULTS
AFFINITY BIOTECH APPOINTS TWO BOARD MEMBERS TO NEW SEATS AND APPOINTS NEW DIRECTOR OF ANALYTICAL SCIENCES
AFFINITY BIOTECH, INC. REPORTS THIRD QUARTER RESULTS
AFFINITY BIOTECH REPORTS SECOND QUARTER RESULTS
AFFINITY BIOTECH AND BIO-PHARM AGREE TO MERGE
Biotech Signs Licensing Agreement to Distribute Its Diabetes Drug, DIAB II, in Argentina.
Biotech Signs Licensing Agreement to Distribute Its Diabetes Drug, DIAB II, in Venezuela.
Biotech Signs Peru Licensing Agreement For Distribution of Its Diabetes Drug, DIAB II.
Amersham Pharmacia Biotech and Dyax Corp. Agree to Develop and Market Innovative Separations Technology.
Biotech Signs Chile Licensing Agreement for Its Diabetes Drug, DIAB II.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters